Genomic Vision: Molecular Combing Featured in an Oral Presentation on CRISPR/Cas9 Gene Editing at the 3rd CSHL Meeting in Ne...
July 27 2017 - 2:00AM
Business Wire
- The results presented demonstrate the
capacity of molecular combing to characterize rearrangements formed
as a result of CRISPR/Cas9-induced breaks and improve biosafety
assessment of gene editing.
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of diagnostic solutions for early
cancer detection, genetic diseases and tools for life sciences
research, today announced that the result of its collaboration with
one of the leading genome editing companies has been presented
during an oral presentation* at the 3rd Cold Spring Harbor
Laboratory Meeting (CSHL) on Genome Engineering, held from July 21
to 23, 2017 in Cold Spring Harbor (NY).
In this collaboration, molecular combing was used to
characterize the type and the frequency of DNA rearrangements
formed as a result of CRISPR/Cas9-mediated gene editing on two
disease loci. The results obtained with molecular combing
complemented those provided by other approaches and contributed to
a more comprehensive safety evaluation of the editing
protocols.
Dr Lucia Cinque, Director of Product Innovation at Genomic
Vision and co-author of the presentation, says: “The results of
this study further reinforce our belief in the value of molecular
combing for the development of safe genome editing applications.
This is particularly important for therapeutic use, where
quantification of rearrangements coupled with a thorough
characterization of the ensuing cellular response is critical. This
fruitful collaboration has not only shown the potential of
molecular combing to leading experts in the field; it has also
enabled Genomic Vision to promptly initiate key product
improvements in order to facilitate a more wide-spread adoption of
its technology as one of the essential tools for the quality and
safety control of advanced genome editors.”
* Presentation Title: “Characterization of genomic
rearrangements in response to CRISPR/Cas9-induced double strand
breaks”(https://meetings.cshl.edu/abstracts.aspx?meet=CRISPR&year=17)
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for early cancer detection, genetic diseases
and tools for life sciences research. Through the DNA Molecular
Combing, a versatile technology allowing to identify genetic
abnormalities, GENOMIC VISION stimulates the R&D productivity
of the pharmaceutical companies, the leaders of the diagnostic
industry and the research labs. The Company develops a robust
portfolio of diagnostic tests (breast, ovarian and colorectal
cancers, myopathies) and analysis tools (DNA replication,
biomarkers discovery, gene editing quality control). Based near
Paris, in Bagneux, the Company has approximately 55 employees.
GENOMIC VISION is a public listed company listed in compartment C
of Euronext’s regulated market in Paris (Euronext: GV - ISIN:
FR0011799907). For further information, please visit
www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170726006184/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorMilestonesPress
RelationsBruno Arabian, +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel Huynh, +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Sep 2023 to Sep 2024